#biotechnology #Switzerland #ACROBiosystems #Zurich

ACROBiosystems Innovation Day: A Hub of Biotech Advancements in Zurich

On May 18, 2026, ACROBiosystems successfully hosted its Innovation Day at the Superlab Suisse Zürich Schlieren, a notable center for innovation in Switzerland. This event brought together leading scientists, translational research experts, and industry innovators to discuss advancements in the development of biopharmaceuticals and translational science.

The lively atmosphere fostered engaging discussions and opportunities for networking among attendees. The event was designed to explore emerging technologies, constantly evolving regulatory landscapes, and new strategies that expedite the journey from discovery to clinical application. It featured cutting-edge development platforms and case studies that provided a focused and high-value program aimed at fostering collaboration and sparking innovative ideas.

Distinguished speakers included Dr. Jenny Ann Prange, head of Project Management at Wyss Zurich; Dr. Lili Qin, Vice President of R&D at ACROBiosystems; Dr. Chiara F Magnani from the University Hospital of Zurich; and Dr. Fabien Jammes from Limula. Notably, Dr. Qin delivered a keynote address titled "AI-Powered Next-Generation Protein Engineering in CGT," highlighting ACROBiosystems' application of AI throughout the protein development workflow. This workflow encompasses the prediction of protein structure, de novo design, expression optimization, purification process design, and formulation optimization.

Dr. Qin showcased real-world examples, including an AI-optimized cytokine that achieved a twenty-fold increase in expression yield and a thermostable FGF2 mutant that remains fully active after three days at 37°C. Furthermore, she introduced a highly specific antibody designed to distinguish between Claudin 18.2 and Claudin 18.1 without cross-reactivity. Behind these impressive advancements lies ACROBiosystems' patented AI-powered platform, which integrates computational predictions with high-throughput experimental validation in a closed-loop synthesis system.

This innovation addresses traditional bottlenecks in the industry, such as low expression yields, thermal instability, and specificity challenges that have historically hindered the development of biopharmaceutical products and cell therapy manufacturing. By incorporating AI into every stage of reagent protein development, ACROBiosystems aims to help the industry achieve higher success rates, shorter timelines, and more scalable pathways from discovery to clinical applications.

The Innovation Day also featured impactful contributions from leading translational research institutions. Dr. Prange shared insights into bridging the gap between early-stage discovery and clinical application in her talk, "Translating Ideas to Reach Those in Need." She outlined one of the most critical hurdles in drug development: transitioning from exploratory R&D to a regulated Good Manufacturing Practices (GMP) environment. Dr. Prange explained how Wyss Zurich combines funding, infrastructure, and translational expertise to assist promising projects in overcoming this complex challenge.

Dr. Chiara Magnani presented clinical insights on CAR-T cell therapy, discussing her research involving genetically modified anti-CD19 CAR-T cells in treating patients with B-cell acute lymphoblastic leukemia (B-ALL). Her presentation, "Advances in Non-Viral Engineered CAR-T Cell Therapy," revealed an 83% complete remission rate with long-term persistence from her study of 36 patients. Additionally, she introduced a modular AdFITC-CAR T platform designed to allow for flexible and adjustable targeting based on multiaromic analyses that identified tumor microenvironment immunosuppression as a key barrier.

Addressing the complexities of cellular therapy manufacturing, Dr. Fabien Jammes spoke on "Decentralized Manufacturing of Cell Therapies: How Compact Automation is Transforming the Landscape." He presented Limula's integrated LimONE platform, which combines bioreactor and centrifuge functions in a single closed device, demonstrating fully automated CAR-T cell manufacturing in just seven days at clinical scale. This decentralization aims to bring manufacturing closer to patients, facilitating quicker access and reduced costs.

Dr. Agnese Pisano and Dr. Aaron Debon from INOBEA tackled manufacturing challenges through enzyme immobilization in their talk, "Immobilized Enzymes for Smart Manufacturing of Biological Products: Applications in mRNA and ADC Production." They discussed their patented technology that enhances enzyme stability and reuse, showcasing case studies on T7 RNA polymerase immobilization for in vitro transcription systems and sortase immobilization for constructing antibody-drug conjugates (ADCs).

Together, these presentations illustrated both the opportunities and challenges inherent in modern biological development, covering AI-optimized proteins, non-viral CAR-T technologies, and automated manufacturing processes. While each speaker approached the topic from different angles, they all emphasized the importance of open collaboration in driving innovation.

Giacomo Cattaruzzi, Innovation Director at Muvon Therapeutics AG, expressed enthusiasm about the event: "This is a great event bringing together academic and industry leaders in the Zurich area. Thanks to ACROBiosystems for the organization. I would be interested in attending future events like this; please keep me informed."

Mike Chen, President and CEO of ACROBiosystems, stated, "We are delighted to have successfully organized the ACROBiosystems Innovation Day in Europe. Innovation is one of our core brand commitments. We look forward to continuing this event to foster global biotech innovation and contribute more significantly to advancing the industry."

About ACROBiosystems Group

Founded in 2010 and publicly listed since 2021, ACROBiosystems Group aspires to be a cornerstone of the global biopharmaceutical and healthcare industries by delivering innovative products and business models. With a global presence that includes offices, R&D centers, and manufacturing bases across more than 15 cities in the United States, Switzerland, the United Kingdom, and Germany, ACROBiosystems has established numerous long-term strategic partnerships with leading pharmaceutical companies like Pfizer, Novartis, and Johnson & Johnson, as well as recognized academic institutions.

ACROBiosystems consists of several subsidiaries, including ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics. Its product offerings encompass recombinant proteins, kits, antibodies, scientific services, and related products. The company implements a stringent quality control system for its products, which are utilized in biopharmaceutical research and development, production, and clinical application.

Through continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers its partners, expediting drug development processes, including targeted therapies and immunotherapeutic drugs, ultimately contributing to global health.